Bausch + Lomb has successfully obtained the CE mark for its latest Luxlife intraocular lens, enabling the company to introduce this advanced product in Europe. The Luxlife lens is designed to support near, intermediate, and far vision, offering a comprehensive solution for patients' visual needs. This innovation differs from the company's Envista IOLs, which faced a temporary recall due to raw material issues causing inflammatory reactions but have since returned to the market. Bausch + Lomb's Lux range introduces distinct optical technologies that minimize light loss to the retina, enhancing overall visual outcomes.
Dr. Yehia Hashad, Chief Medical Officer at Bausch + Lomb, highlighted the differences between Lux and Envista lenses during an earnings call. Luxlife lenses incorporate two key technologies ensuring no light is lost to the retina, improving performance compared to diffractive full-range vision lenses. Clinical trials conducted by Cutting Edge demonstrated excellent binocular vision results across all distances, with significant percentages of users achieving glasses-free vision. The company plans to roll out non-toric and toric versions of Luxlife soon. CEO Brent Saunders also announced plans for a soft launch of Envista Envy in Europe later this year, with a broader rollout scheduled for early 2026.
Revolutionizing Vision Correction: Luxlife Lens Technology
Bausch + Lomb's Luxlife intraocular lens represents a leap forward in vision correction technology. Unlike traditional lenses, Luxlife leverages innovative non-diffractive optical design combined with advanced diffractive technology. These features ensure that no light is lost on its journey to the retina, significantly enhancing visual clarity and quality. By addressing common issues associated with diffractive lenses, such as light loss, Luxlife delivers superior outcomes across all distances—near, intermediate, and far.
The development of Luxlife stems from extensive research and collaboration with leading experts in the field. During clinical trials conducted by Cutting Edge, recipients of the Luxlife lens experienced exceptional binocular vision results. Notably, 89.5% and 95.6% of users reported being able to see without glasses at near and intermediate distances, respectively. This groundbreaking achievement highlights the effectiveness of Luxlife's unique design. Furthermore, the trial compared Luxlife with the monofocal Luxgood lens, underscoring its superiority in providing comprehensive vision correction. As a result, Bausch + Lomb is poised to offer a non-toric version of Luxlife shortly, followed closely by a toric version designed to correct astigmatism.
Strategic Expansion and Market Introduction Plans
Bausch + Lomb’s strategic approach to introducing Luxlife into the European market reflects a well-planned rollout strategy. With the CE mark approval secured, the company is set to initiate the launch of the non-toric Luxlife lens within the coming weeks. Following this initial release, the toric version will be introduced shortly after, targeting individuals with astigmatism. Such a phased introduction ensures smooth integration and optimal adoption by healthcare providers and patients alike.
In addition to Luxlife, Bausch + Lomb has outlined ambitious plans for other products in its pipeline. CEO Brent Saunders revealed intentions for a soft launch of Envista Envy in Europe later this year, building momentum towards a full-scale rollout anticipated in early 2026. Despite previous challenges with Envista lenses, including recalls due to inflammatory reactions, the company has identified and resolved the underlying causes, ensuring safety and reliability moving forward. This commitment to continuous improvement underscores Bausch + Lomb’s dedication to delivering cutting-edge solutions in vision care, positioning the company as a leader in the industry.